153 related articles for article (PubMed ID: 34048085)
21. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
22. Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement.
Bai Y; Sun W; Niu D; Yang X; Diao X; Yu Y; Lin D
Virchows Arch; 2021 Dec; 479(6):1079-1083. PubMed ID: 33825946
[TBL] [Abstract][Full Text] [Related]
23. Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib.
Zhou Y; Hurtado-Castillo M; Pandey O
Front Med (Lausanne); 2023; 10():1288849. PubMed ID: 38093982
[TBL] [Abstract][Full Text] [Related]
24. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
25. Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer.
Nicoś M; Jarosz B; Krawczyk P; Wojas-Krawczyk K; Kucharczyk T; Sawicki M; Pankowski J; Trojanowski T; Milanowski J
Brain Pathol; 2018 Jan; 28(1):77-86. PubMed ID: 27879019
[TBL] [Abstract][Full Text] [Related]
26. A Rare Case of Tracheal Crystal-Storing Histiocytosis Associated with Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.
Kimura S; Oyama Y; Ziyao W; Waseda R; Nishino N; Sakata T; Takeshita M
Int J Surg Pathol; 2022 Aug; 30(5):543-550. PubMed ID: 35075931
[TBL] [Abstract][Full Text] [Related]
27. Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
Yuan C; Ma MJ; Parker JV; Mekhail TM
Am J Case Rep; 2017 Jul; 18():799-804. PubMed ID: 28713152
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
Ou SH
Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
[TBL] [Abstract][Full Text] [Related]
29. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
30. A case report of atypical Spitz tumor harboring a novel MLPH-ALK gene fusion with discordant ALK immunohistochemistry results.
Fujimoto M; Togashi Y; Matsuzaki I; Baba S; Takeuchi K; Inaba Y; Jinnin M; Murata SI
Hum Pathol; 2018 Oct; 80():99-103. PubMed ID: 29514107
[TBL] [Abstract][Full Text] [Related]
31. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
32. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D
Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334
[TBL] [Abstract][Full Text] [Related]
33. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
[TBL] [Abstract][Full Text] [Related]
34. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
35. ALK-positive histiocytosis with
Gupta GK; Xi L; Pack SD; Jones JB; Pittaluga S; Raffeld M; Jaffe ES
Haematologica; 2019 Nov; 104(11):e534-e536. PubMed ID: 31371408
[No Abstract] [Full Text] [Related]
36. Rare childhood hybrid histiocytosis of the central nervous system-diagnosed by stereotactic brain biopsy with marked treatment response to clofarabine.
Foss-Skiftesvik J; Scheie D; Klausen C; Sehested A; Skjøth-Rasmussen J
Childs Nerv Syst; 2018 Nov; 34(11):2321-2324. PubMed ID: 29872899
[TBL] [Abstract][Full Text] [Related]
37. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy.
Chan JK; Lamant L; Algar E; Delsol G; Tsang WY; Lee KC; Tiedemann K; Chow CW
Blood; 2008 Oct; 112(7):2965-8. PubMed ID: 18660380
[TBL] [Abstract][Full Text] [Related]
38. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
39. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
[TBL] [Abstract][Full Text] [Related]
40. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
